In vitro study of regulation of IL-6 production in bronchiectasis  by Ho, James C et al.
In vitro study of regulation of IL-6 production in
bronchiectasis
James C. Hoa, George Tipoeb, L. Zhenga, T.M. Leunga, Kenneth
W.T. Tsanga, Daisy K.Y. Shumc, C.S. Laua, Judith C.W. Maka, W.K. Lama,
Mary S.M. Ipa,*
aDivision of Respiratory and Critical Care Medicine, University Department of Medicine, The University of
Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong SAR, China
bUniversity Department of Anatomy, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR,
China
cUniversity Department of Biochemistry, The University of Hong Kong, Queen Mary Hospital,
Hong Kong SAR, China
Received 8 April 2003; accepted 27 October 2003
Summary Persistent airway inflammation is an important pathogenetic factor in
bronchiectasis, and interleukin (IL)-6 is among the mediators implicated in
regulation of inflammation in bronchiectatic airways. We postulated that airway
secretion with its constituents of cytokines and enzymes would provide an
environment for perpetuation of inflammation in vivo. We aimed to determine the
action of sputum from patients with bronchiectasis on IL-6 production from cultured
normal human bronchial epithelial (NHBE) cells and its modulation by anti-
inflammatory drugs in vitro.
Cultures of NHBE cells were tested with (i) sputum of bronchiectatic patients, (ii)
anti-tumor necrosis factor-alpha (TNF-a) pre-treated sputum, or (iii) recombinant
human (rh)-TNF-a. Alternatively, NHBE cells were incubated with one of the anti-
inflammatory drugs before treatment with sputum or rh-TNF-a. IL-6 produced into
the medium was assayed by ELISA.
Sputum in bronchiectasis stimulated IL-6 production from NHBE cells by 1.9 times.
This was largely attributable to TNF-a as pre-incubation of sputum sol with anti-TNF-
a almost neutralized the sputum effect. Apart from dexamethasone, the other drugs
exerted inhibitory effects on IL-6 production. Ibuprofen suppressed sputum-
stimulated IL-6 production to levels above control and effect levelled off at 50–
100 mg/ml, contrasting the dose-dependent suppression to control level with MK-663
(0.1–10 mg/ml) and to sub-control levels with triptolide (20–1000 ng/ml).
Our results support that sputum in bronchiectasis can stimulate IL-6 production
from NHBE cells, and TNF-a is an important cytokine mediating the process. The
suppressive effects observed with ibuprofen, triptolide and MK-663 warrant further
study.
& 2003 Elsevier Ltd. All rights reserved.
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Introduction
Bronchiectasis, the permanent dilatation of one or
more bronchi, is a common respiratory condition
which occurs in the west in cystic fibrosis, and in
the east as sequelae of respiratory infections or as
etiologically idiopathic cases.1 The pathogenetic
mechanisms in bronchiectasis are multi-faceted
including enzymatic,2 inflammatory,3 and infective4
elements. Sputum in bronchiectatic subjects
has been shown to contain various inflam-
matory cytokines and elastase, which correlated
with disease activity.2 In recent decades,
major advances exploring the inflammatory net-
work in various inflammatory airway diseases
like asthma have broadened our understanding
of the pathogenesis with potential therapeutic
implications.
The respiratory epithelium has long been re-
garded as an inert barrier lining the human airway.
However, there has been abundant evidence
suggesting that the respiratory epithelium plays a
metabolically active role in various conditions like
asthma5 and infections.6 Studies on cultured human
bronchial epithelial cells incubated with bacterial
endotoxin demonstrated a marked increase in
expression and/or release of pro-inflammatory
mediators including interleukin (IL)-6, IL-8, tumor
necrosis factor-alpha (TNF-a) and intercellular
adhesion molecule-1 (ICAM-1).6 IL-6 is often used
as a marker of systemic activation of pro-inflam-
matory cytokines.7
We postulate that the vicious circle of inflamma-
tion in bronchiectasis is maintained in part by the
copious bronchial secretion with its rich contents
of cytokines and enzymes. Recent study has
shown a significant increase in IL-6 among
other cytokines in bronchoalveolar lavage fluid
in subjects with bronchiectasis compared to con-
trol.8 This inflammatory reaction was exaggerated
in subjects colonized by microorganisms with
a clear relationship to the bronchial bacterial
load. Similarly, sputum from subjects with non-
cystic fibrosis diffuse bronchiectasis was found
to have increased IL-6.9 In cystic fibrosis, which
is mainly characterized by diffuse bronchiectasis
in the lungs, plasma IL-6 levels after an exacerba-
tion were reduced after antibiotic treatment,
acting as a maker of inflammation.10 In this
study, we explore the effect of sputum sol
from subjects with bronchiectasis on the produc-
tion of IL-6 from normal human bronchial epithelial
(NHBE) cells and the role of sputum TNF-a in
this aspect. The potential effects of four anti-
inflammatory drugs on IL-6 production were also
evaluated.
Materials and methods
Sample collection
Subjects with clinically and radiologically (based on
high-resolution computed tomography (HRCT) scan)
confirmed bronchiectasis were identified at the
respiratory clinic in the Queen Mary Hospital in
Hong Kong. Only those with clinical steady-state
bronchiectasis were recruited. Subjects with acute
infective episodes requiring antibiotics in the prior
3 weeks, and those on long-acting b2 agonists,
anticholinergics, theophylline or steroids were
excluded. Short-acting inhaled bronchodilator
therapy was withheld in the morning of sputum
collection. The quality of expectorated sputum was
examined under light microscopy with presence of
X10 buccal epithelial cells being considered
salivary in origin and excluded for further experi-
ments. Fresh sputum samples were collected in
sterile pots for 4 h from waking up in the morning,
and ultracentrifuged at 50,000 g for 90min at
41C. The supernatants (sputum sol) were separated
and stored at 801C for subsequent experiments.
This study has been approved by the Ethics
Committee, the University of Hong Kong.
Reagents
Lyophilized recombinant human (rh)-TNF-a (PePro
Tech EC Ltd, London, UK) was reconstituted in
sterilized water and aliquoted for subsequent use.
Anti-human TNF-a (PePro Tech EC Ltd, London, UK)
was a rabbit-derived polyclonal antibody with
neutralizing activity against TNF-a which was
quantitated in a cytolysis assay. Dexamethasone
and ibuprofen (both from Sigma, St. Louis, MO,
USA) were prepared according to the instructions
from the provider. Triptolide was kindly provided by
Professor DQ Yu (Chinese Academy of Medical
Sciences, Beijing, China) and was isolated accord-
ing to the method previously described.11 MK-663
(COX-2 inhibitor) was obtained from the Merck
Research Laboratory.
Primary culture of human bronchial
epithelial cells
One ampoule of primary NHBE cells (lot number:
8F0148, age 18, female; lot number: 8F0258, age
47, male) (Clonetics, San Diego, CA, USA) was
thawed in a 371C water bath and seeded to T-75
culture flasks containing basal medium with supple-
ments at seeding density of 3500 cells/cm2. The
supplements added were 30mg/ml bovine pituitary
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extract (BPE), 0.5 mg/ml hydrocortisone, 0.5 mg/ml
recombinant human epidermal growth factor
(hEGF), 0.5 mg/ml epinephrine, 10 mg/ml transfer-
rin, 5 mg/ml insulin, 0.1 mg/ml retinoic acid, 6.5 mg/
ml triiodothyronine, 50 mg/ml gentamcin, 50 mg/ml
amphotericin-B and 500 mg/ml bovine serum albu-
min-fatty acid free (BSA-FAF) (Clonetics). Cells
were incubated at 371C and 5% CO2. Upon 70–80%
confluence, cells were recovered with trypsin/
ethylenediaminetetraacetic acid (EDTA). The third
generation of NHBE cells were cultured in 12-well
plates coated with Collagen IV until 80% confluence
for subsequent experiments. Cell viability was
randomly checked to ensure no significant differ-
ence during various experiments. Specifically,
Trypan Blue Exclusion Test was done on separate
sets of cell cultures to ascertain that cells were
viable after incubation with the highest concentra-
tion of each drug used in the study.
Assays of TNF-a and IL-6
The concentration of TNF-a and IL-6 in the sputum
sol and supernatant of cell culture medium were
measured by enzyme-linked immunoabsorbent as-
say (ELISA) (Amersham Pharmacia Biotech, Piscat-
away, NJ, USA). In brief, biotinylated antibody
reagent was added to each well of a 96-well
polystyrene microtitre ELISA plate coated with an
antibody against the cytokine of interest. Standards
and samples were then added in duplicate to the
wells and incubated for 2 h at room temperature.
After the incubation, each well was washed
vigorously with wash buffer for three times.
Streptavidin-horse reddish peroxidase was added
to each well and incubated for 30min at room
temperature followed by washing three times with
wash buffer. TMB substrate solution was then added
into each well and incubated for another 30min at
room temperature in the dark. At the end of
incubation, stop solution was added to each well of
the ELISA plate. The assays were calibrated with
the standard provided with the kits and optical
densities were measured by a microplate reader at
the wavelength of 450 nm.
Treatment of NHBE cells with sputum sol,
anti-TNF-a or rh-TNF-a
Sputum sol samples were diluted 50-fold with basal
medium, added to NHBE cells (lot 8F0148) cultured
in 12-well plates and incubated at 371C and 5% CO2
for 4 h. Triplicate treatments were performed for
each sputum sol sample. Parallel incubations of
NHBE cells in culture medium were taken as
controls. After the incubations, the media were
recovered and the cell-free supernatants were
assayed for IL-6.
To neutralize possible effects of sputum sol TNF-a
on the NHBE cells, cultures in 12-well plates were
incubated (4 h, 371C) with 50-fold dilutions of sol
samples which had been treated (1 h, 371C) with
anti-TNF-a at concentrations (5.75–10.45 mg/ml)
commensurate with TNF-a levels in the sol samples.
Parallel incubations of NHBE cell cultures with anti-
TNF-a were used as controls.
Alternatively, to confirm the effect of sputum sol
TNF-a, rh-TNF-a was added to NHBE cells at a
concentration corresponding to TNF-a levels (1.15–
2.09 ng/ml) in individual sputum sol samples. The
effect of rh-TNF-a on IL-6 secretion into the
medium was compared with those due to incuba-
tions with sputum sol samples.
Treatment of NHBE cells with anti-
inflammatory drugs
To further study the potential effects of various
anti-inflammatory drugs on the stimulated IL-6
production, NHBE cells (lot 8F0258) were pre-
incubated (1 h, 371C) with one of four anti-
inflammatory drugs: dexamethasone (stock solu-
tion, 100mg/ml in methanol; working, 4 ng/ml
(0.01 mM), 40 ng/ml (0.1 mM) and 400 ng/ml
(1 mM)), ibuprofen (stock solution, 100mg/ml in
methanol; working, 50 mg/ml (242 mM), 80 mg/ml
(388 mM) and 100 mg/ml (485 mM)), triptolide (stock
solution, 2.5mg/ml in ethanol/acetone (1/1, v/v);
working 20, 200 and 1000 ng/ml) and MK-663 (0.1, 1
and 10 mg/ml). The drug concentrations were
chosen based on data from previously published
studies12–14 or from the supplier (Merck Research
Laboratory for MK-663). The effect of drug vehicle
on IL-6 production was also studied by pre-
incubating NHBE cells with different concentrations
of methanol, ethanol and acetone. The drug-
treated cultures were then exposed either to
sputum sol samples (at 50-fold dilution) or rh-
TNF-a (at concentrations comparable to that in the
diluted sol samples) for another 4 h at 371C. After
the incubation, the medium was recovered and the
cell-free supernatant was assayed for IL-6. Results
were compared with those of corresponding cul-
tures incubated in control medium.
Statistical analysis
The IL-6 levels measured in the experiments were
expressed as mean7SEM. Statistical significance was
tested by Wilcoxon signed ranks test for paired data
ARTICLE IN PRESS
336 J.C. Ho et al.
and Mann–Whitney U-test for independent data.
Significance was accepted at Po0:05: All the
statistical tests were done by SPSS version 10.0
(SPSS Inc., Chicago, IL, USA).
Results
Levels of TNF-a and IL-6 in sputum sol
samples
Ten Chinese subjects (five males, age 54715 years)
with non-cystic fibrosis bronchiectasis were re-
cruited. All subjects were never smokers. In all
study subjects, HRCT scan of thorax showed
features of cylindrical type diffuse bronchiectasis.
The cause of bronchiectasis was classified as
idiopathic in all cases. Secondary causes of
bronchiectasis, including infections especially tu-
berculosis, congenital or acquired immunodefi-
ciency and primary ciliary dyskinesia, were
excluded. Pseudomonas aeruginosa was isolated
from sputum in three cases, Haemophilus
influenzae in one case and commensals in six cases.
Lung function indices included forced expiratory
volume in 1 s (FEV1) 64726% predicted and forced
vital capacity (FVC) 80721% predicted. Six sub-
jects had their sputum sol samples measured for
TNF-a (1.5570.34 ng/ml) and the corresponding
sputum IL-6 concentrations were undetectable
(less than 10.24 pg/ml, the detection limit of the
ELISA).
TNF-a in sputum sol stimulates IL-6
production by NHBE cells
Exposure of cultures of NHBE cells to sputum sol
samples (n ¼ 10) found elevated IL-6 levels in the
medium 1.970.2 times as high as that found in
parallel incubations of NHBE cells in culture
medium alone (45.6729.1 pg/ml). As TNF-a was
invariably found in expectorated sputum samples of
patients with bronchiectasis, attempts were made
to neutralize its effect by pre-incubation of the sol
samples with commensurate levels of a polyclonal
antibody against human TNF-a. Exposure of
NHBE cells to antibody-treated sol samples indeed
resulted in IL-6 levels almost as low as those of
cells exposed simply to the culture medium
(1.170.1 times, P40:05 compared to control).
To confirm that the sputum-stimulated effect was
due to TNF-a, cells were exposed instead to
rh-TNF-a at a concentration corresponding to the
mean TNF-a found in the sputum sol samples. IL-6
concentration in rh-TNF-a-treated cultures was
found to be 5.370.6 times that of cells exposed
to culture medium alone (Po0:05). Thus TNF-a
is an important factor in the sputum cytokine
network that stimulates IL-6 production by NHBE
cells.
Anti-inflammatory drugs vary in effects on
IL-6 production by NHBE cells
The effects of anti-inflammatory drugs on TNF-a-
mediated IL-6 production in NHBE cells were then
studied. Consistently, rh-TNF-a-stimulated IL-6 pro-
duction by NHBE cells could effectively be down-
regulated by all four anti-inflammatory drugsF
dexamethasone, ibuprofen and MK-633 brought
levels down to 2–3 times that in control medium
whereas triptolide remained the most effective in
that IL-6 levels could be lowered to 60% of that in
control medium (Fig. 1).
Similarly, experiments were also performed to
test for drugs that can counter the IL-6 production
by sputum-stimulated NHBE cells. Sputum sol
samples obtained from all 10 subjects with idio-
pathic bronchiectasis were used for the experi-
ments. Among the drugs tested, dexamethasone
(4–400 ng/ml) showed no suppressive effect on
sputum-stimulated cell production of IL-6 (Fig.
2A). Instead of inhibition, an additional increase
in IL-6 level, at 15–20% above those indicated by
sputum-stimulated cells was detected in media of
cells treated with dexamethasone (P40:05).
Although ibuprofen (50–100 mg/ml), a non-steroidal
anti-inflammatory drug (NSAID), could to an extent
counter sputum-stimulated IL-6 production, IL-6
levels remained at 1.5–1.8 times as high as those of
cells in the control medium (Fig. 2B). The NHBE
cells, however, appeared more responsive to
treatments with the two experimental drugs, MK-
663 (COX-2 inhibitor) and triptolide. MK-663 (0.1–
10.0 mg/ml) resulted in dose-dependent suppres-
sion of sputum-stimulated IL-6 production, to levels
that approach that of cells in the control medium
(Fig. 2C). Triptolide (20–1000 ng/ml) also resulted
in dose-dependent suppression of sputum-stimu-
lated IL-6 production, but to levels as low as 24% of
cells in the control medium (Fig. 2D). Altogether, at
the highest concentrations of drugs used in the
experiments, triptolide (1000 ng/ml) had the great-
est inhibitory effect on sputum sol-stimulated IL-6
production. On the other hand, pre-incubation of
NHBE cells with drug vehicles (methanol, ethanol,
acetone) at different concentrations showed no
significant effect on IL-6 production (data not
shown).
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Discussion
In this study, we have demonstrated that sputum
sol samples from subjects with bronchiectasis
contain stimulatory factors for IL-6 production by
NHBE cells in vitro, and identified that TNF-a in the
sputum plays an important role in the induction of
IL-6 production in bronchial epithelial cells. Among
the anti-inflammatory drugs tested in the study,
ibuprofen, a COX-2 inhibitor MK-663 and triptolide
but not dexamethasone showed clear inhibitory
effects on IL-6 production from bronchial epithelial
cells after stimulation with sputum from bronch-
iectatic subjects.
TNF-a has been isolated in significant levels in
bronchiectasis,2 and has been found to be an
important mediator in the cytokine network for
tissue degradation.15 Several studies have sug-
gested TNF-a and IL-1b as the major stimulatory
cytokines for IL-6 production in human bronchial
epithelial cells16,17 and human airway smooth
muscle cells.18 The stimulation with rh-TNF-a in
our study resulted in effective up-regulation of IL-6
production by NHBE cells, which was consistent
with previous studies. The apparently more effec-
tive stimulation of IL-6 production with rh-TNF-a
than sputum sol samples could be due to inactiva-
tion of TNF-a in sputum or presence of other
cytokines in sputum that inhibit IL-6 production. On
the other hand, pre-incubation of sputum sol
samples with anti-TNF-a antibody could drastically
suppress IL-6 production from NHBE cells, ap-
proaching the basal level secreted by blank-
stimulated cells. Since the action of anti-TNF-a
antibody is specifically targeted to TNF-a, the
marked inhibitory effect of anti-TNF-a antibody
on IL-6 production suggests an important role of
TNF-a in the inflammatory cytokine network. This is
analogous to the principle for recent anti-cytokine
therapy in rheumatoid arthritis.19 The various pro-
inflammatory cytokines interact with each other
leading to propagation of inflammation. Basic and
clinical studies have shown that application of
neutralizing anti-TNF-a antibody can effectively
improve the inflammation in rheumatoid arthritis,
which involves many other cytokines as well, such
as IL-1, GM-CSF and IL-6.20–22 Therefore the loss of
activity of one major mediator causes breakdown
of the inflammatory network resulting in cessation
of inflammation.
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Figure 1 Inhibitory effects of all four anti-inflammatory drugs on IL-6 in recombinant human TNF-a-stimulated NHBE
cells. Dexamethasone (4, 40, 400 ng/ml), ibuprofen (50, 80, 100 mg/ml), MK-663 (0.1, 1, 10 mg/ml) and triptolide (20,
200, 1000 ng/ml) all showed inhibitory effect on rh-TNF-a induced IL-6 production (Po0:05 for the differences in IL-6
levels between the highest drug concentrations and control with rh-TNF-a). IL-6 levels were expressed relative to those
in cells cultured in control medium (45.6729.1 pg/ml).
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Since bronchiectasis is considered as an inflam-
matory airway disease,2 there has been great
interest in the potential use of various anti-
inflammatory drugs to overcome the inflammatory
cascade. Dexamethasone, an analog of glucocorti-
coids, is a potent immunosuppressive agent and is
widely used in airway inflammation-related dis-
eases. There are studies showing that dexametha-
sone can effectively down-regulate the level of IL-6
production mediated by rh-TNF-a on human airway
smooth muscle cells,18 lipopolysaccharide on mono-
cytic cell line,23 and rhinovirus on human tracheal
epithelial cells.24 In our study, dexamethasone
showed no inhibitory effect on IL-6 production
after stimulation with sputum sol samples from
bronchiectasis subjects. However, in NHBE cells
stimulated with rh-TNF-a, dexamethasone showed
effective though incomplete suppression of IL-6
production. This suggests that despite effective
down-regulation of IL-6 production by TNF-a with
dexamethasone, there are stimulatory factors
other than TNF-a in the sputum sol that are not
inhibited by the action of dexamethasone. This
supports the presence of a network of cytokines
actively participating in the inflammatory process.
Even when the major pro-inflammatory cytokine
TNF-a is deactivated, other pro-inflammatory cyto-
kines which go through alternative pathways are
still working.
Ibuprofen, a NSAID, inhibits the enzyme cyclo-
oxygenase (both COX-1 and COX-2) which is crucial
in the formation of prostaglandins thereby leading
to suppression of inflammation. It has been
associated with an increased,25–28 decreased,29,30
or unchanged31 pro-inflammatory cytokine secre-
tion. In particular, ibuprofen has been found to
increase IL-6 in endotoxic mice,27 and decrease IL-6
in human peripheral blood mononuclear cells.32 A
novel NSAID, lornoxicam, has also been found to
suppress IL-6 production in lipopolysaccharide-
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Figure 2 Inhibitory effects of anti-inflammatory drugs on IL-6 in sputum sol-stimulated NHBE cells. (A) Lack of
inhibitory effect of dexamethasone at 4, 40 and 400 ng/ml on sputum sol-stimulated NHBE cells. (B) Ibuprofen at 50, 80
and 100 mg/ml suppressed IL-6 in sputum sol-stimulated NHBE cells. The inhibitory effect reached a plateau at
ibuprofen concentration 50 mg/ml. (C) MK-633 at 0.1, 1 and 10 mg/ml suppressed IL-6 in sputum sol-stimulated NHBE
cells. There was a dose-dependent inhibitory effect across the different concentrations of MK-633 tested. (D) Tiptolide
at 20, 200 and 1000 ng/ml suppressed IL-6 in sputum sol-stimulated NHBE cells. There was a dose-dependent inhibitory
effect across the different concentrations of triptolide tested. Statistically significant differences were indicated on the
graphs. IL-6 levels were expressed relative to those in cells cultured in control medium (45.6729.1 pg/ml).
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stimulated monocytic cells (THP-1).33 In fact,
recent study suggested that ibuprofen inhibited
the activation and translocation of the key tran-
scriptional factor nuclear factor-kappa B (NF-kB) by
blocking the degradation of inhibitor-kB-a, a
protein that forms a complex with NF-kB, thus
preventing the release and subsequent transloca-
tion of NF-kB into the nucleus and the expression of
inflammatory cytokines.30 Our results support an
inhibitory role of ibuprofen on IL-6 production from
NHBE cells stimulated with bronchiectatic sputum
sol but this inhibitory effect reached a plateau at
low concentration of the drug (50 mg/ml). Similar
results could also be demonstrated in NHBE cells
stimulated with rh-TNF-a.
Recent studies suggest that cyclo-oxygenase
exists in a constitutive form (COX-1) and an
inducible form (COX-2) in which the latter is
predominantly related to inflammation.34 The use
of selective COX-2 inhibitors has been proven to
have potent anti-inflammatory actions while avoid-
ing major adverse effects by preserving the COX-1
activity.34–37 Therapeutic administration of a selec-
tive COX-2 inhibitor, SC-58125, could rapidly
reverse inflammation in rat adjuvant arthritis and
reduce serum IL-6 and paw IL-6 mRNA levels to near
normal levels.38 Similarly, in NHBE cells, we could
demonstrate in this study an efficient and dose-
dependent down-regulation of bronchiectatic spu-
tum sol-induced IL-6 production with a novel COX-2
inhibitor MK-663. This inhibitory effect on IL-6 was
also found in NHBE cells stimulated with rh-TNF-a.
Therefore, our results suggest the predominant role
of COX-2 isoform in the airway inflammation
related to bronchiectasis.
Triptolide is a diterpenoid triepoxide purified
from a Chinese herb Tripterygium Wilfordii Hook F
(TWHF) which has long been used in traditional
Chinese medicine for the treatment of leprosy and
rheumatoid arthritis. It affects T cell activation
through inhibition of IL-2 transcription at a site
different from the target of cyclosporin A.39 It also
up-regulates the mRNA expression of inhibitor-kB-a
in a dose-dependent fashion thereby decreasing the
NF-kB activity in T lymphocytes.14 In human
bronchial epithelial cells, triptolide inhibits normal
and transformed cell expression of IL-6 and IL-8
after stimulation by phorbol 12-myristate 13-
acetate (PMA), TNF-a, or IL-1b.11 The results of
this study demonstrated clearly that triptolide
could efficiently down-regulate the IL-6 production
from NHBE cells on stimulation with bronchiectatic
sputum sol. This inhibitory effect occurred in a
dose-dependent fashion. Similarly, triptolide could
also inhibit IL-6 production in NHBE cells stimulated
with rh-TNF-a.
Despite recent works on the functions of IL-6 in
various inflammatory models, the exact role of IL-6
has been controversial. IL-6 has been regarded to
have both pro-inflammatory and anti-inflammatory
properties.40 In acute infections, IL-6 may be
important mediator of acute phase reaction to
defend against sepsis. In the setting of chronic
disease especially in the presence of viral or
bacterial infections, IL-6 serves as an important
player in the elicitation of cellular immune
responses against affected cells and of mucosal
humoral responses against reinfection.41 However,
an over-exuberant response may not be desirable in
conditions like bronchiectasis, where the response
to microorganisms is up-regulated but ineffective
in eradication of the organism, and many of the
pathologic features are attributed to the severe
inflammatory response. On the other hand, over-
suppression of IL-6 production, as demonstrated by
using triptolide at highest concentration, may also
be detrimental. We have previously demonstrated
significant reduction of sputum leukocyte density
and IL-1b, IL-8 and LTB4 with inhaled corticosteroid
(fluticasone) treatment in patients with non-cystic
fibrosis bronchiectasis.42 The exact implications of
regulation of cytokine production with drugs in
clinical management of bronchiectasis should be
further explored.
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